Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OmniAb, Inc. (OABI : NSDQ)

• Company Description    OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO. Number of Employees: 114

• Price / Volume Information    Yesterday's Closing Price: $1.38 Daily Weekly Monthly 20 Day Moving Average: 544,310 shares Shares Outstanding: 143.96 (millions) Market Capitalization: $198.66 (millions) Beta: 0.15 52 Week High: $4.63 52 Week Low: $1.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.55% -16.79% 12 Week -31.34% -34.19% Year To Date -61.02% -65.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 Horton Street Suite 600 - Emeryville,CA 94608 USA ph: 510-250-7800 fax: - investors@omniab.com http://www.omniab.com

• General Corporate Information    Officers Matthew W. Foehr - President and Chief Executive Officer and Director John L. Higgins - Director and Chairman of the Board Kurt Gustafson - Executive Vice President; Finance and Chief Financ Carolyn R. Bertozzi - Director Sarah Boyce - Director Peer Information OmniAb, Inc. (GSAC) OmniAb, Inc. (CASI) OmniAb, Inc. (ALCD.) OmniAb, Inc. (OMNN) OmniAb, Inc. (CGPI.) OmniAb, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68218J103 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 143.96 Most Recent Split Date: (:1) Beta: 0.15 Market Capitalization: $198.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.72 Price/Cash Flow: - Price / Sales: 9.42 EPS Growth vs. Year Ago Period: 12.50% vs. Previous Quarter: 6.67% Sales Growth vs. Year Ago Period: -46.33% vs. Previous Quarter: -42.55% ROE 09/30/25 - -23.14 06/30/25 - -22.79 03/31/25 - -21.37 ROA 09/30/25 - -20.59 06/30/25 - -20.18 03/31/25 - -18.84 Current Ratio 09/30/25 - 5.00 06/30/25 - 3.77 03/31/25 - 4.70 Quick Ratio 09/30/25 - 5.00 06/30/25 - 3.77 03/31/25 - 4.70 Operating Margin 09/30/25 - -301.83 06/30/25 - -275.83 03/31/25 - -229.11 Net Margin 09/30/25 - -301.83 06/30/25 - -275.83 03/31/25 - -229.11 Pre-Tax Margin 09/30/25 - -317.49 06/30/25 - -296.89 03/31/25 - -254.78 Book Value 09/30/25 - 1.93 06/30/25 - 2.14 03/31/25 - 2.24 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©